- Home
- UL vs BMY Comparison
UL vs BMY Comparison
Compare UL & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UL | BMY |
|---|---|---|
| Founded | 1930 | 1887 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.9B | 113.5B |
| IPO Year | 1999 | 2006 |
Fundamental Metrics
Financial Performance| Metric | UL | BMY |
|---|---|---|
| Price | $61.65 | $63.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $61.73 |
| AVG Volume (30 Days) | 3.6M | ★ 7.3M |
| Earning Date | 03-12-2026 | 04-30-2026 |
| Dividend Yield | 4.04% | ★ 4.38% |
| EPS Growth | N/A | ★ 178.46 |
| EPS | N/A | ★ 2.93 |
| Revenue | N/A | ★ $48,194,000,000.00 |
| Revenue This Year | $2.53 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | ★ $14.29 | $21.98 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $54.75 | $42.52 |
| 52 Week High | $74.98 | $68.64 |
Technical Indicators
Market Signals| Indicator | UL | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 39.17 | 43.44 |
| Support Level | $61.38 | $63.00 |
| Resistance Level | $63.61 | $68.37 |
| Average True Range (ATR) | 0.78 | 1.27 |
| MACD | -0.34 | -0.56 |
| Stochastic Oscillator | 0.50 | 4.47 |
Price Performance
Historical ComparisonAbout UL Unilever PLC
Unilever is a diversified beauty, wellbeing, and personal care (51% of 2025 sales by value), homecare (23%), and packaged food (26%) company. Its brands include Dove personal-care products, Knorr soups and sauces, Hellmann's mayonnaise, Axe and Rexona deodorants, and TRESemmé haircare. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, and Wild deodorants. The company derives 58% of its sales from emerging markets and 42% from developed markets. The US is its largest market, accounting for around 20% of sales, followed by India, which accounts for 11% of sales.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.